Preferred Label : Allogeneic CRISPR-edited Anti-CD19 CAR T Cells PACE CART19;
NCIt synonyms : Allogeneic Anti-CD19 CAR T-cells PACE CART19; Allogeneic Anti-CD19 CAR-T Cells PACE CART19; PACE CART19; Allogeneic Anti-CD19 CAR T Cells PACE CART19; PACE CART19 Cells;
NCIt definition : An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes transduced with
a lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD19
single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137)
coupled to the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), and
electroporated with clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9
nuclease complex to eliminate the expression of endogenous TCR, HLA class I and HLA
class II molecules, with potential immunostimulating and antineoplastic activities.
Upon administration, allogeneic CRISPR-edited anti-CD19 CAR T cells PACE CART19 recognize
and bind to CD19-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte
(CTL)-mediated killing of CD19-expressing tumor cells. The removal of endogenous TCR,
HLA class I and HLA class II molecules prevents allogeneic immune responses and reduces
the risk of graft-versus-host disease (GvHD). The tumor-associated antigen (TAA) CD19
is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.;
NCI Metathesaurus CUI : CL1772549;
Origin ID : C184372;
UMLS CUI : C5669238;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
